MedTrace Logo

Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.

NCT04350164 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2020-12-28

No results posted yet for this study

Summary

The rationale for this retrospective study is to evaluate the efficacy and safety of thrombopoietin-receptor agonist (TPO-RA) romiplostim for reducing thrombocytopenia and bleeding tendency in pediatric participants with genetically confirmed Wiskott-Aldrich syndrome (WAS).

Conditions

  • Wiskott-Aldrich Syndrome

Interventions

DRUG

Romiplostim

romiplostim once weekly subcutaneously at an initial dose of 8-9 µg/kg per week for at least 1 month to 1 year.

Sponsors & Collaborators

  • Federal Research Institute of Pediatric Hematology, Oncology and Immunology

    lead OTHER

Principal Investigators

  • Anna Shcherbina, MD, PhD · National Research Center for Pediatric Hematology , Moscow, Russian Federation

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-01
Primary Completion
2019-12-27
Completion
2020-06-30

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04350164 on ClinicalTrials.gov